HomeIONS • NASDAQ
add
Ionis Pharmaceuticals Inc
Previous close
$38.39
Day range
$38.19 - $39.02
Year range
$35.95 - $54.44
Market cap
6.11B USD
Avg Volume
1.47M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Jun 2024info | Y/Y change |
|---|---|---|
Revenue | 225.25M | 19.55% |
Operating expense | 65.11M | 41.11% |
Net income | -66.26M | 22.31% |
Net profit margin | -29.42 | 35.01% |
Earnings per share | -0.24 | 40.89% |
EBITDA | -63.00M | 27.53% |
Effective tax rate | -0.10% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Jun 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 2.09B | -12.87% |
Total assets | 2.69B | -9.42% |
Total liabilities | 2.43B | -4.54% |
Total equity | 263.70M | — |
Shares outstanding | 146.21M | — |
Price to book | 21.21 | — |
Return on assets | -6.06% | — |
Return on capital | -7.30% | — |
Cash Flow
Net change in cash
| (USD) | Jun 2024info | Y/Y change |
|---|---|---|
Net income | -66.26M | 22.31% |
Cash from operations | -119.88M | -23.13% |
Cash from investing | 62.45M | -10.16% |
Cash from financing | 2.56M | -98.22% |
Net change in cash | -54.90M | -147.42% |
Free cash flow | -101.02M | -120.17% |
About
Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics. The company has three commercially approved medicines: Spinraza, Tegsedi, and Waylivra, and has four drugs in pivotal studies: tominersen for Huntington's disease, tofersen for SOD1-ALS, AKCEA-APO-LRx for cardiovascular disease, and AKCEA-TTR-LRx for all forms of TTR amyloidosis.
The company was named Isis Pharmaceuticals until December 2015. Wikipedia
Founded
1989
Headquarters
Website
Employees
927
